Volume 74, Issue 3, Pages (September 2018)

Slides:

Advertisements

Similar presentations

Volume 50, Issue 3, Pages (September 2006)

Advertisements

Medical Management for BPH: The Role of Combination Therapy

Volume 59, Issue 2, Pages (February 2011)

Volume 64, Issue 3, Pages (September 2013)

Volume 73, Issue 3, Pages (March 2018)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 64, Issue 5, Pages (November 2013)

Jean-Jacques Wyndaele European Urology Supplements

Volume 70, Issue 1, Pages (July 2016)

Volume 73, Issue 1, Pages (January 2018)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Debra E. Irwin, Ian Milsom, Zoe Kopp, Paul Abrams European Urology

Volume 50, Issue 5, Pages (November 2006)

Volume 71, Issue 4, Pages (April 2017)

Volume 65, Issue 1, Pages (January 2014)

Volume 52, Issue 3, Pages (September 2007)

Treatment of Nightmares With Prazosin: A Systematic Review

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 45, Issue 4, Pages (April 2004)

Volume 61, Issue 1, Pages (January 2012)

Volume 64, Issue 4, Pages (October 2013)

Volume 64, Issue 4, Pages (October 2013)

Volume 56, Issue 1, Pages (July 2009)

Volume 59, Issue 2, Pages (February 2011)

Volume 63, Issue 1, Pages (January 2013)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 51, Issue 1, Pages (January 2007)

Volume 54, Issue 4, Pages (October 2008)

The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review

Volume 56, Issue 3, Pages (September 2009)

Volume 62, Issue 3, Pages (September 2012)

Volume 70, Issue 3, Pages (September 2016)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 1, Pages (July 2011)

Volume 55, Issue 3, Pages (March 2009)

Volume 72, Issue 3, Pages (September 2017)

Volume 70, Issue 1, Pages (July 2016)

Yuanshan Cui, Yong Zhang European Urology

Volume 65, Issue 2, Pages (February 2014)

Volume 58, Issue 5, Pages (November 2010)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

The Economic Costs of Overactive Bladder in Germany

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 54, Issue 4, Pages (October 2008)

Volume 73, Issue 3, Pages (March 2018)

Volume 72, Issue 2, Pages (August 2017)

Volume 70, Issue 1, Pages (July 2016)

Single-Incision Mini-Slings Versus Standard Midurethral Slings in Surgical Management of Female Stress Urinary Incontinence: A Meta-Analysis of Effectiveness.

Volume 51, Issue 1, Pages (January 2007)

Volume 74, Issue 6, Pages (December 2018)

Volume 74, Issue 5, Pages (November 2018)

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Volume 73, Issue 2, Pages (February 2018)

Volume 75, Issue 2, Pages (February 2019)

Volume 52, Issue 3, Pages (September 2007)

European Urology is “Your” Journal

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 75, Issue 1, Pages (January 2019)

Volume 74, Issue 4, Pages (October 2018)

Volume 50, Issue 2, Pages (August 2006)

Efficacy of low frequency pulsed subsensory threshold electrical stimulation vs placebo on pain and physical function in people with knee osteoarthritis:

Profile of Silodosin European Urology Supplements

Systematic Review of Complications of Prostate Biopsy

Classification of Mixed Incontinence

Economic and Social Impact of OAB

Volume 75, Issue 6, Pages (June 2019)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 74, Issue 3, Pages 324-333 (September 2018) Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis Con Kelleher, Zalmai Hakimi, Richard Zur, Emad Siddiqui, Khaled Maman, Samuel Aballéa, Jameel Nazir, Chris Chapple European Urology Volume 74, Issue 3, Pages 324-333 (September 2018) DOI: 10.1016/j.eururo.2018.03.020 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 PRISMA flow diagram showing study selection process and rationale for exclusions. EMBASE=Excerpta Medica database; NMA=network meta-analysis; PRISMA=Preferred Reporting Items for Systematic Reviews and Meta-Analyses. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Efficacy of mirabegron 50mg versus antimuscarinics: (A) micturition frequency (mean change from baseline in number of episodes/24h); (B) UUI (mean change from baseline in number of episodes/24h); (C) dry rate (number of patients with zero incontinence episodes or 100% reduction in incontinence episodes) a; and (D) 50% reduction in incontinence episodes (number of patients) b. CrI=credible intervals; ER=extended release; Mir=mirabegron; Sol=solifenacin; UUI=urgency urinary incontinence. a No UUI episodes or 100% reduction in UUI episodes were used as the definition for dry rate in seven studies, including the following comparators: placebo, fesoterodine, trospium, and tolterodine ER. b For 50% reduction in incontinence episodes, all data for fesoterodine (one placebo-controlled trial) are based on reduction of UUI only. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Tolerability of mirabegron 50mg versus antimuscarinics (all number of patients): (A) dry mouth, (B) constipation, (C) blurred vision, and (D) hypertension. CrI=credible intervals; ER=extended release; IR=immediate release; Mir=mirabegron; Sol=solifenacin. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020) Copyright © 2018 European Association of Urology Terms and Conditions